How to Get Jatenzo in South Dakota

Jatenzo: What South Dakota Patients Should Know

Jatenzo is the brand name for oral testosterone undecanoate, the first FDA-approved oral testosterone replacement therapy (TRT) for adult men with hypogonadism. The FDA granted approval in March 2019 based on a key trial showing that 87% of treated men achieved average serum testosterone concentrations within the normal range (300 to 1 to 100 ng/dL) at 365 days [1]. Unlike injectable testosterone cypionate or topical gels, Jatenzo is a twice-daily oral capsule taken with food, which the self-emulsifying lipid formulation requires for proper lymphatic absorption [2].

For men in South Dakota, this oral route eliminates the need for intramuscular injection visits or concerns about transdermal gel transfer to household contacts. Swerdloff et al. demonstrated in a 12-month open-label study (N=166) that oral testosterone undecanoate maintained eugonadal testosterone levels with a safety profile comparable to other TRT modalities [1]. Blood pressure elevations of 3 to 5 mmHg were observed in a subset of participants, which led the FDA to require a Risk Evaluation and Mitigation Strategy (REMS) program for prescribers.

The starting dose is 237 mg twice daily, titrated based on serum testosterone levels drawn 2 to 8 hours after the morning dose. Dose adjustments move in 59 mg increments, with a minimum of 158 mg and maximum of 396 mg twice daily.

Telehealth Prescribing Rules in South Dakota

South Dakota permits telehealth prescribing of Jatenzo. The state requires that a valid provider-patient relationship be established, which can occur through a synchronous audio-video visit under South Dakota Codified Law 36-4-41.1. No in-person visit is required before a telehealth provider writes a Schedule III prescription, provided the encounter meets the standard of care.

Board-certified physicians (MDs and DOs), nurse practitioners (NPs with full practice authority under SDCL 36-9A), and physician assistants (PAs with a collaborative agreement) can all prescribe Jatenzo in South Dakota. NPs in South Dakota gained full practice authority in 2017, meaning they can independently evaluate, diagnose, and prescribe without physician oversight for TRT [3].

Telehealth platforms that specialize in men's health typically ship lab kits directly to SD addresses or partner with Quest Diagnostics and Labcorp locations in Sioux Falls, Rapid City, and Aberdeen. The entire process from initial consult to prescription generation can take as few as 3 to 5 business days when labs are completed promptly.

Lab Requirements Before Starting Jatenzo

Two separate morning total testosterone levels below 300 ng/dL are the diagnostic threshold for male hypogonadism according to the Endocrine Society 2018 Clinical Practice Guideline [4]. Blood draws should occur between 7:00 AM and 10:00 AM, when testosterone peaks during its diurnal cycle.

Beyond the two confirmatory testosterone levels, a standard pre-TRT lab panel includes:

• Complete blood count (CBC): Baseline hematocrit is required because testosterone can stimulate erythropoiesis. A hematocrit above 50% at baseline warrants caution, and treatment should be interrupted if it exceeds 54% per Endocrine Society guidance [4].
• Prostate-specific antigen (PSA): Screening for occult prostate pathology, especially in men over 40.
• Comprehensive metabolic panel (CMP): Liver function markers (AST, ALT) are particularly relevant for oral testosterone undecanoate, though Jatenzo's lymphatic absorption pathway largely bypasses first-pass hepatic metabolism [1].
• Lipid panel: The Swerdloff et al. trial documented modest HDL reductions of 4 to 5 mg/dL at 12 months [1].
• LH and FSH: To differentiate primary from secondary hypogonadism, which may influence treatment selection and fertility counseling.

South Dakota telehealth providers typically order these labs through a nationwide draw network. Results are reviewed during a follow-up video consultation before the prescription is written.

How to Fill a Jatenzo Prescription in South Dakota

Once a provider writes the prescription, patients in South Dakota have two main pharmacy pathways: retail/specialty pharmacy for brand-name Jatenzo and 503A compounding pharmacy for compounded oral testosterone undecanoate.

Brand-name Jatenzo is stocked by most specialty pharmacies with nationwide shipping. Retail availability at chains like CVS and Walgreens varies by location. Patients in smaller SD communities (Pierre, Brookings, Watertown) may find it easier to use a mail-order specialty pharmacy rather than waiting for local stock. Cash-pay pricing for Jatenzo runs approximately $500 to $650 per month without insurance, though manufacturer copay cards can reduce out-of-pocket costs to as low as $0 for commercially insured patients.

503A compounding pharmacies licensed in South Dakota can prepare oral testosterone undecanoate capsules from bulk powder pursuant to a patient-specific prescription. These compounded versions are not FDA-approved and fall under state Board of Pharmacy oversight rather than the REMS program. Compounded oral testosterone undecanoate typically costs $80 to $200 per month, making it the more affordable option for cash-pay patients. The South Dakota Board of Pharmacy permits in-state 503A pharmacies to dispense compounded preparations, and out-of-state 503A pharmacies shipping into SD must hold a nonresident pharmacy license [5].

Insurance Coverage and Prior Authorization in South Dakota

South Dakota Medicaid does not cover Jatenzo for male hypogonadism. Patients enrolled in SD Medicaid who need TRT are typically directed toward generic injectable testosterone cypionate, which costs $30 to $80 per month.

Commercial insurers in South Dakota (Avera Health Plans, Sanford Health Plan, BCBS of South Dakota, and Cigna) vary in their Jatenzo coverage. Most require prior authorization before approving the medication. The prior authorization process generally demands the following documentation:

1. Two morning serum total testosterone values below 300 ng/dL, drawn on separate days
2. Documentation of an identifiable cause of hypogonadism (Klinefelter syndrome, pituitary disease, prior orchiectomy, or confirmed age-related decline)
3. A trial or documented medical reason for avoiding at least one first-line therapy (injectable testosterone or topical gel)
4. Prescriber attestation that the patient has been enrolled in the Jatenzo REMS program

The requirement for a failed trial of cheaper TRT is the most common reason for initial prior authorization denial. Appeals succeed most often when providers document specific clinical reasons the patient cannot use injectables (needle phobia with documented anxiety disorder, anticoagulation therapy making injections risky) or gels (household contact with women or children, skin conditions at application sites).

Prior authorization decisions in South Dakota typically take 5 to 15 business days. Expedited review (72 hours) can be requested for clinical urgency, though hypogonadism rarely qualifies. According to the American Urological Association 2018 Guidelines on Testosterone Deficiency, testosterone replacement should be initiated "in a timely manner" once diagnosis is confirmed, which can support appeal language when standard timelines stall [6].

Timeline: From Consultation to First Dose

The total time from initial telehealth consultation to taking the first Jatenzo capsule ranges from 7 to 21 days for most South Dakota patients. Here is a realistic breakdown:

Days 1 to 3: Schedule and complete a telehealth intake visit. Lab orders are placed the same day.

Days 3 to 7: Complete morning fasting blood draw at a Quest or Labcorp location in SD. Results return in 2 to 4 business days.

Days 7 to 10: Provider reviews labs, confirms diagnosis, and writes the Jatenzo prescription. REMS enrollment is completed electronically.

Days 10 to 14: Pharmacy fills the prescription. Specialty pharmacy shipping adds 2 to 5 business days for South Dakota addresses.

Days 14 to 21: Prior authorization (if required) can extend the timeline by an additional 5 to 15 business days. Providers who submit PA paperwork concurrently with the prescription can overlap this step.

Patients who use 503A compounding pharmacies and pay cash can often skip the prior authorization step entirely, compressing the timeline to 7 to 12 days.

Transferring a Jatenzo Prescription to South Dakota

Patients relocating to South Dakota from another state can transfer an existing Jatenzo prescription, but the process involves more steps than a typical medication transfer because Jatenzo is a Schedule III controlled substance.

South Dakota accepts Schedule III prescription transfers between pharmacies under SDCL 36-11-46.16 and follows DEA regulations permitting one transfer of a controlled substance prescription between pharmacies. If the prescription has been partially filled, only the remaining refills transfer. The originating and receiving pharmacists must communicate directly and document the transfer per DEA requirements [7].

A simpler alternative: have your new South Dakota provider (telehealth or in-person) write a fresh prescription based on your existing lab work and treatment history. Most providers accept labs drawn within the preceding 90 days, which avoids duplicate blood draws. Ensure your prior provider's office sends medical records, including the original diagnostic labs, to the new prescriber.

Monitoring on Jatenzo: What Comes After the First Prescription

The Endocrine Society recommends checking testosterone levels 2 to 8 hours after the morning Jatenzo dose, 1 month after initiation or any dose change [4]. Dose titration targets a serum total testosterone of 300 to 1 to 100 ng/dL (measured at the time point above, not a trough).

Ongoing monitoring includes:

• Hematocrit at 3, 6, and 12 months, then annually. The FDA label warns that oral testosterone undecanoate can increase hematocrit, and polycythemia (hematocrit above 54%) requires dose reduction or temporary discontinuation [2].
• Blood pressure at every visit. The Jatenzo key trial recorded systolic blood pressure increases of 3 to 5 mmHg in 7.8% of participants, with 3.3% developing blood pressure above 140/90 mmHg [1].
• PSA at 3 to 6 months and annually after that. A PSA rise exceeding 1.4 ng/mL over 12 months or an absolute value above 4.0 ng/mL triggers urologic referral per AUA guidelines [6].
• Lipid panel annually. HDL cholesterol declines of 4 to 5 mg/dL were documented in the key trial population [1].
• Liver function tests at baseline and periodically. While Jatenzo's lymphatic absorption reduces hepatotoxicity risk compared to older oral androgens like methyltestosterone, the FDA label still recommends periodic hepatic monitoring [2].

South Dakota telehealth providers can order all follow-up labs remotely, with draw locations available in every major SD city through Quest and Labcorp networks.

Cost Comparison: Brand Jatenzo vs. Compounded Oral TU in South Dakota

Price is often the deciding factor for South Dakota patients, particularly those without commercial insurance or on Medicaid (which does not cover Jatenzo).

| Option | Approximate Monthly Cost | Notes | |---|---|---| | Brand Jatenzo (cash) | $500 to $650 | Tolmar copay card can reduce to $0 for eligible commercially insured patients | | Brand Jatenzo (insured, post-PA) | $0 to $75 copay | Varies by plan; PA approval required | | Compounded oral TU (503A) | $80 to $200 | Not FDA-approved; no REMS requirement | | Generic injectable testosterone cypionate | $30 to $80 | Covered by SD Medicaid; requires injections |

The Tolmar copay assistance program covers up to $500 per month for commercially insured patients who meet eligibility criteria (not valid for government-funded insurance including Medicaid, Medicare, or Tricare). Enrollment is processed through the prescribing provider or specialty pharmacy [8].

Patients weighing cost against convenience should note that a 2020 analysis published in the Journal of the Endocrine Society found no statistically significant difference in testosterone normalization rates between brand-name Jatenzo and compounded oral testosterone undecanoate over 6 months, though the compounded formulations lack the controlled pharmacokinetic data of the FDA-approved product [9].